PMID: 9647334Jul 1, 1998Paper

Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus

Journal of Diabetes and Its Complications
Vivian A FonsecaL M Fink

Abstract

The objective of this study was to determine if treatment of non-insulin-dependent diabetes mellitus (NIDDM) patients with the "insulin sensitizer" troglitazone, both as monotherapy and in combination with insulin, corrects the impaired fibrinolysis and activated coagulation associated with NIDDM. Patients participating in two clinical trials comparing troglitazone and placebo in patients with NIDDM were studied at the time of randomization and after 26 weeks of treatment. Eighteen patients were treated with troglitazone (ten in combination with insulin and eight as monotherapy) and eight were treated with placebo (four in each trial). Plasma concentrations of plasminogen activator inhibitor (PAI-1), prothrombin fragment F1+2, fibrinogen, and von Willebrand Factor (vWF) activity were measured. Plasma PAI-1 concentrations fell significantly from a mean of 68.8 +/- 32.3 ng/mL to 40.4 +/- 20.4 in the troglitazone treated group, but did not change significantly in the placebo treated group. Plasma PAI-1 concentrations were elevated in 15 patients treated with troglitazone and fell to normal in eight of them. There was no significant change in plasma F1+2, vWF, and fibrinogen, but plasma C-peptide and triglyceride concentrations fel...Continue Reading

References

Jan 1, 1992·Haemostasis·A CerielloF Gonano
Sep 1, 1990·Atherosclerosis·M MehrabianA J Lusis
Nov 16, 1987·Clinica Chimica Acta; International Journal of Clinical Chemistry·G UrdénB Wiman
Nov 3, 1994·The New England Journal of Medicine·J J NolanJ Olefsky
Aug 1, 1993·Metabolism: Clinical and Experimental·B J Potter van LoonA E Meinders
Jan 1, 1997·Thrombosis Research·P GalajdaP Kubisz

❮ Previous
Next ❯

Citations

Oct 16, 1999·Comprehensive Therapy·A A Parulkar, V A Fonseca
Feb 3, 2005·Current Atherosclerosis Reports·Brandy PanuntiVivian Fonseca
Sep 2, 2003·Current Hypertension Reports·Jonathan P CastroJames R Sowers
Jan 1, 2003·Comprehensive Therapy·Biswanath P GoudaVivian A Fonseca
Sep 6, 2003·The American Journal of Cardiology·Vivian A Fonseca
Dec 1, 2001·Endocrinology and Metabolism Clinics of North America·J A Colwell
Jun 25, 2002·Diabetes Technology & Therapeutics·Joel Berger, John A Wagner
May 1, 2004·Diabetes Technology & Therapeutics·Shanti Serdy, Martin J Abrahamson
Mar 29, 2008·Metabolic Syndrome and Related Disorders·Sunil AsnaniVivian A Fonseca
Mar 29, 2008·Metabolic Syndrome and Related Disorders·Kathleen L Wyne
Mar 29, 2008·Metabolic Syndrome and Related Disorders·Julie P SutherlandRobert H Eckel
Oct 18, 2006·Clinical and Experimental Pharmacology & Physiology·Mohammad AllahtavakoliBijan Djahanguiri
Oct 13, 2005·Diabetes, Obesity & Metabolism·M Krebs, M Roden
Jun 17, 2006·Diabetes, Obesity & Metabolism·Kathleen L Wyne
Aug 19, 2007·Expert Opinion on Pharmacotherapy·Andreas PfütznerThomas Forst
Apr 24, 2009·Clinical and Experimental Hypertension : CHE·Katsutaka Oishi
Dec 30, 2015·PPAR Research·Amanda CroasdellRichard P Phipps
Sep 24, 2004·Diabetic Medicine : a Journal of the British Diabetic Association·D M ReboussinJ Williamson
Jul 23, 2005·International Journal of Clinical Practice. Supplement·R A DeFronzo
May 25, 2010·Journal of Thrombosis and Haemostasis : JTH·B A LemkesJ B L Hoekstra
Dec 18, 2003·The American Journal of Medicine·Manuel A Gonzalez, Andrew P Selwyn
Dec 18, 2003·The American Journal of Medicine·Christopher J Lyon, Willa A Hsueh
Oct 7, 2004·Cardiovascular Radiation Medicine·Rajbabu PakalaRon Waksman
Jan 4, 2006·Journal of Diabetes and Its Complications·Vivian A FonsecaRobert R Henry
Jul 21, 2004·Endocrinology and Metabolism Clinics of North America·Daniel EinhornRobert R Henry
Mar 9, 2005·Endocrinology and Metabolism Clinics of North America·Biju P KunhiramanVivian A Fonseca
Sep 17, 2002·The American Journal of Cardiology·Jane E B Reusch
Sep 17, 2002·The American Journal of Cardiology·Harold E Lebovitz
May 9, 2002·Expert Opinion on Pharmacotherapy·Anastassios G Pittas, Andrew S Greenberg
Feb 13, 2001·Annual Review of Medicine·S Mudaliar, R R Henry

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.